A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621

Lung Cancer

Volumn 85, Issue 2, 2014, Pages 245-250

  Molina, Julian R ^a   Foster, Nathan R ^a   Reungwetwattana, Thanyanan ^g   Nelson, Garth D ^a   Grainger, Andrew V ^b   Steen, Preston D ^c   Stella, Philip J ^d   Marks, Randolph ^a   Wright, John ^e   Adjei, Alex A ^f  

^a MAYO CLINIC   (United States)

^b Hematology/Oncology Consultants Inc   (United States)

^c MeritCare Hospital   (United States)

^d Department of Obstetrics and Gynecology   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f ROSWELL PARK CANCER INSTITUTE   (United States)

^g MAHIDOL UNIVERSITY   (Thailand)

Author keywords

C Src; Extensive stage; Maintenance; Saracatinib; Small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; SARACATINIB; 1,3 BENZODIOXOLE DERIVATIVE; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; DRUG EFFICACY; DRUG TOLERANCE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HYPOKALEMIA; LUNG SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT REFUSAL; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DISEASE COURSE; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; RETREATMENT; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZODIOXOLES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RETREATMENT; SMALL CELL LUNG CARCINOMA; SRC-FAMILY KINASES; TREATMENT OUTCOME;

EID: 84904106107     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.03.004     Document Type: Article

References (38)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics. CA Cancer J Clin 2010, [Epub ahead of print July 7].
2. Govindan R., Page N., Morgensztern D., et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006, 24(28):4539-4544.
3. Jackman D.M., Johnson B.E. Small-cell lung cancer. Lancet 2005, 366(9494):1385-1396.
4. Evans W.K., Shepherd F.A., Feld R., et al. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol 1985, 3(11):1471-1477.
5. Roth B.J., Johnson D.H., Einhorn L.H., et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992, 10(2):282-291.
6. Pujol J.L., Carestia L., Daures J.P. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 2000, 83(1):8-15.
7. Sundstrom S., Bremnes R.M., Kaasa S., et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 2002, 20(24):4665-4672.
8. Lally B.E., Urbanic J.J., Blackstock A.W., et al. Small cell lung cancer: have we made any progress over the last 25 years?. Oncologist 2007, 12(9):1096-1104.
9. Thomas S.M., Brugge J.S. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 1997, 13:513-609.
10. Windham T.C., Parikh N.U., Siwak D.R., et al. Src activation regulates anoikis in human colon tumor cell lines. Oncogene 2002, 21(51):7797-7807.
11. Wong B.R., Besser D., Kim N., et al. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol Cell 1999, 4(6):1041-1049.
12. Arron J.R., Vologodskaia M., Wong B.R., et al. A positive regulatory role for Cbl family proteins in tumor necrosis factor-related activation-induced cytokine (trance) and CD40L-mediated Akt activation. J Biol Chem 2001, 276(32):30011-30017.
13. Roelle S., Grosse R., Buech T., Chubanov V., Gudermann T. Essential role of Pyk2 and Src kinase activation in neuropeptide-induced proliferation of small cell lung cancer cells. Oncogene 2008, 27(March (12)):1737-1748.
14. Masaki T., Igarashi K., Tokuda M., et al. pp60c-src activation in lung adenocarcinoma. Eur J Cancer 2003, 39(10):1447-1455.
15. Zhang J., Kalyankrishna S., Wislez M., et al. SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am J Pathol 2007, 170(1):366-376.
16. Green T., Hennequin L., Ple P., et al. Pre-clinical and early clinical activity of the highly selective, orally available, dual Src/Abl kinase inhibitor AZD0530. AACR Annual Meeting SSY01 Drugs on The Horizon Symposium 2005.
17. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92(3):205-216.
18. Kaplan E., Meier P. Nonparametric estimation for incomplete observation. J Am Stat Assoc 1958, 53:457-481.
19. Mascaux C., Paesmans M., Berghmans T., et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 2000, 30(1):23-36.
20. Kosmidis P.A., Samantas E., Fountzilas G., et al. Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Hellenic Cooperative Oncology Group for Lung Cancer Trials. Semin Oncol 1994, 21(3 (Suppl. 6)):23-30.
21. Skarlos D.V., Samantas E., Kosmidis P., et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol 1994, 5(7):601-607.
22. Frame M.C. Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta 2002, 1602(2):114-130.
23. Laird A.D., Li G., Moss K.G., et al. Src family kinase activity is required for signal tranducer and activator of transcription 3 and focal adhesion kinase phosphorylation and vascular endothelial growth factor signaling in vivo and for anchorage-dependent and -independent growth of human tumor cells. Mol Cancer Ther 2003, 2(5):461-469.
24. Song L., Turkson J., Karras J.G., et al. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 2003, 22(27):4150-4165.
25. Eliceiri B.P., Paul R., Schwartzberg P.L., et al. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell 1999, 4(6):915-924.
26. Dy G.K., Miller A.A., Mandrekar S.J., et al. A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol 2005, 16(11):1811-1816.
27. Krug L.M., Crapanzano J.P., Azzoli C.G., et al. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial. Cancer 2005, 103(10):2128-2131.
28. Spigel D.R., Hainsworth J.D., Simons L., et al. Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network. J Thorac Oncol 2007, 2(9):854-861.
29. Moore A.M., Einhorn L.H., Estes D., et al. Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial. Lung Cancer 2006, 52(1):93-97.
30. Pandya K.J., Dahlberg S., Hidalgo M., et al. A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500). J Thorac Oncol 2007, 2(11):1036-1041.
31. Rudin C.M., Salgia R., Wang X., et al. Randomized phase II study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol 2008, 26(6):870-876.
32. Heymach J.V., Johnson D.H., Khuri F.R., et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer. Ann Oncol 2004, 15(8):1187-1193.
33. Shepherd F.A., Giaccone G., Seymour L., et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002, 20(22):4434-4439.
34. Govindan R., Wang X., Baggstrom M.Q., et al. A phase II study of carboplatin, etoposide, and exisulind in patients with extensive small cell lung cancer: CALGB 30104. J Thorac Oncol 2009, 4(2):220-226.
35. Lara P.N., Chansky K., et al. Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327). J Thorac Oncol 2006, 1(9):996-1001.
36. Miller A.A., Pang H., Hodgson L., et al. A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602). J Thorac Oncol 2010, 5(3):380-384.
37. Ready N., Dudek A.Z., Wang X.F., et al. CALGB 30306: a phase II study of cisplatin (C), irinotecan (I) and bevacizumab (B) for untreated extensive stage small cell lung cancer (ES-SCLC). J Clin Oncol ASCO Annu Meet Proc I 2007, 25:7563.
38. Sandler A., Szwaric S., Dowlati A., et al. A phase II study of cisplatin (P) plus etoposide (E) plus bevacizumab (B) for previously untreated extensive stage small cell lung cancer (SCLC) (E3501): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol ASCO Annu Meeting Proc I 2007, 25:7564.